Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 9;3(13):2022–2034. doi: 10.1182/bloodadvances.2019000194

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by The American Society of Hematology

PMC Copyright notice

Figure 1. — Clinical responses (ITT population). (A) Patient response profiles. Swimmer plot showing duration of clinical response and survival after disease progression. Patients 207, 256, and 264 were disease progression-free at more than 3 years post-NY-ESO-1^c259 T-cell therapy. Day 0, ASCT; day 2, NY-ESO-1^c259 T-cell infusion. (B) PFS, Kaplan-Meier plot. Surviving (censored) patients are represented by tick marks. (C) OS, Kaplan-Meier plot. Surviving (censored) patients are represented by tick marks.